Association between time to progression and subsequent survival inceritinib-treated patients with advanced ALK-positive non-small-cell lung cancer

References

• National Cancer Institute. SEER Stat Fact Sheets: Lung and Bronchus Cancer. Surveillance, Epidemiology, and End Results Program (SEER). Available at: http://seer.cancer.gov/statfacts/html/lungb.html [Last accessed 15 January 2016]
   Google Scholar
• Reck M, Popat S, Reinmuth N, et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25:iii27-39
   PubMed Web of Science ®Google Scholar
• Howlader N, Noone A, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2010. Bethesda, MD: National Cancer Institute, 2013
   Google Scholar
• National Comprehensive Cancer Network. Non-Small Cell Lung Cancer, version 4.2014. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Fort Washington, PA: National Comprehensive Cancer Network, 2014
   Google Scholar
• Villaruz, LC, Socinski, MA. Personalized therapy for non-small cell lung cancer: which drug for which patient? Semin Thorac Cardiovasc Surg 2011;23:281-90
   PubMedGoogle Scholar
• Yi Wang KK. Predictive and prognostic value of ALK gene rearrangement in non- small cell lung cancer. Epidemiology: Open Access 2014
   Google Scholar
• Paik JH, Choi CM, Kim H, et al. Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma. Lung Cancer 2012;76:403-9
   PubMed Web of Science ®Google Scholar
• Takeda M, Okamoto I, Sakai K, et al. Clinical outcome for EML4-ALK-positive patients with advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy. Ann Oncol 2012;23:2931-6
   PubMed Web of Science ®Google Scholar
• Yang P, Kulig K, Boland JM, et al. Worse disease-free survival in never-smokers with ALK + lung adenocarcinoma. J Thorac Oncol 2012;7:90-7
   PubMed Web of Science ®Google Scholar
• Costa DB, Kobayashi S, Pandya SS, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 2011;29:e443-5
   PubMed Web of Science ®Google Scholar
• Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011;12:1004-12
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Ceritinib Drug Prescribing Information. 2014. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205755lbl.pdf [Last accessed 21 April 2015]
   Google Scholar
• Felip E, Kim D, Mehra R, et al. Efficacy and safety of ceritinib in patients (pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): an update of ASCEND-1. Ann Oncol 2014;25:iv456-7
   Google Scholar
• Shaw AT, Kim D-W, Mehra R, et al. Ceritinib in ALK-rearranged non–small-cell lung cancer. N Engl J Med 2014;370:1189-97
   PubMed Web of Science ®Google Scholar
• Mok T, Spigel D, Felip E, et al. ASCEND-2: a single-arm, open-label, multicenter phase II study of ceritinib in adult patients (pts) with ALK-rearranged (ALK+) non-small cell lung cancer (NSCLC) previously treated with chemotherapy and crizotinib (CRZ). ASCO Annual Meeting Proceedings 2015;33:8059
   Google Scholar
• Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non–small-cell lung cancer. N Engl J Med 2005;353:123-32
   PubMed Web of Science ®Google Scholar
• Sun Y, Wu Y-L, Zhou C-C, et al. Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: a randomized, open-label study. Lung Cancer 2013;79:143-50
   PubMed Web of Science ®Google Scholar
• Kim ES, Neubauer M, Cohn A, et al. Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial. Lancet Oncol 2013;14:1326-36
   PubMed Web of Science ®Google Scholar
• Karampeazis A, Voutsina A, Souglakos J, et al. Pemetrexed versus erlotinib in pretreated patients with advanced non–small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study. Cancer 2013;119:2754-64
   PubMed Web of Science ®Google Scholar
• Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non–small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-97
   PubMed Web of Science ®Google Scholar
• Garassino MC, Martelli O, Broggini M, et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol 2013;14:981-8
   PubMed Web of Science ®Google Scholar
• McMeekin S, Dizon D, Barter J, et al. Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer. Gynecol Oncol 2015;138:18-23
   PubMed Web of Science ®Google Scholar
• Yasui H, Muro K, Shimada Y, et al. A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study. J Cancer Res Clin Oncol 2015;141:153-60
   PubMed Web of Science ®Google Scholar
• Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94
   PubMed Web of Science ®Google Scholar
• Korhonen P, Zuber E, Branson M, et al. Correcting overall survival for the impact of crossover via a rank-preserving structural failure time (RPSFT) model in the RECORD-1 trial of everolimus in metastatic renal-cell carcinoma. J Biopharm Stat 2012;22:1258-71
   PubMed Web of Science ®Google Scholar
• Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012;13:528-38
   PubMed Web of Science ®Google Scholar
• Pilz LR, Manegold C, Schmid-Bindert G. Statistical considerations and endpoints for clinical lung cancer studies: can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer? Transl Lung Cancer Res 2012;1:26-35
   PubMedGoogle Scholar
• Suzuki H, Hirashima T, Okamoto N, et al. Relationship between progression-free survival and overall survival in patients with advanced non-small cell lung cancer treated with anticancer agents after first-line treatment failure. Asia Pac J Clin Oncol 2015;11:121-8
   PubMed Web of Science ®Google Scholar
• Fleischer F, Gaschler-Markefski B, Bluhmki E. A statistical model for the dependence between progression-free survival and overall survival. Stat Med 2009;28:2669-86
   PubMed Web of Science ®Google Scholar
• LDK378 in adult patients with ALK-activated NSCLC previously treated with chemotherapy and crizotinib. 2015. Available at: https://clinicaltrials.gov/ct2/show/NCT01685060 [Last accessed 7 April 2015]
   Google Scholar
• Referenced with permission from NCCN Clinical Practice Guidelines in Oncology Non-Small Cell Lung Cancer. v 5. Available at: http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf [Last Accessed 20 August 2015]
   Google Scholar
• Cox DR. Regression models and life-tables. In: Kotz S, Johnson NL, eds. Breakthroughs in Statistics: Methodology and Distribution. New York, NY: Springer New York, 1992:527-41
   Google Scholar
• Négrier S, Bushmakin AG, Cappelleri JC, et al. Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma. Eur J Canc 2014;50:1766-71
   PubMed Web of Science ®Google Scholar
• Ou SH, Janne PA, Bartlett CH, et al. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann Oncol 2014;25:415-22
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, Schwedler K, Schmidt M, et al. Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur J Canc 2011;47:2273-81
   PubMed Web of Science ®Google Scholar
• von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German breast group 26/breast international group 03-05 study. J Clin Oncol 2009;27:1999-2006
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Non-Small Cell Lung Cancer, version 2.2013. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Fort Washington, PA: National Comprehensive Cancer Network, 2013
   Google Scholar
• Isozaki H, Takigawa N, Kiura K. Mechanisms of acquired resistance to ALK inhibitors and the rationale for treating ALK-positive lung cancer. Cancers 2015;7:763-83
   PubMed Web of Science ®Google Scholar
• Shaw AT and Solomon B. Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancer. 2014. Available at: http://www.uptodate.com/contents/anaplastic-lymphoma-kinase-alk-fusion-oncogene-positive-non-small-cell-lung-cancer [Last accessed 31 March 2016]
   Google Scholar
• Shaw AT, Friboulet L, Leshchiner I, et al. Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F. N Engl J Med 2016;374:54-61
   PubMed Web of Science ®Google Scholar
• Tan DSW, Liu G, Kim DW, et al. Continuation of ceritinib beyond disease progression is associated with prolonged post-progression survival (PPS) in ALK + NSCLC. Poster presentation. 6th European Lung Cancer Conference (ELCC). Geneva, Switzerland, 2016
   Google Scholar
• Giobbie-Hurder A, Gelber RD, Regan MM. Challenges of guarantee-time bias. J Clin Oncol 2013;31:2963-9
   PubMed Web of Science ®Google Scholar
• Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989;8:431-40
   PubMed Web of Science ®Google Scholar